132 related articles for article (PubMed ID: 1706960)
1. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity.
Maione TE; Gray GS; Hunt AJ; Sharpe RJ
Cancer Res; 1991 Apr; 51(8):2077-83. PubMed ID: 1706960
[TBL] [Abstract][Full Text] [Related]
2. Induction of inhibitory activity for B cell differentiation in human CD8 T cells with pokeweed mitogen, dimaprit, and cAMP upregulating agents: countersuppressive effect of platelet factor 4.
Crisi GM; Katz IR; Zucker MB; Thorbecke GJ
Cell Immunol; 1996 Sep; 172(2):205-16. PubMed ID: 8964082
[TBL] [Abstract][Full Text] [Related]
3. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
Vandercappellen J; Liekens S; Bronckaers A; Noppen S; Ronsse I; Dillen C; Belleri M; Mitola S; Proost P; Presta M; Struyf S; Van Damme J
Mol Cancer Res; 2010 Mar; 8(3):322-34. PubMed ID: 20215425
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.
Kolber DL; Knisely TL; Maione TE
J Natl Cancer Inst; 1995 Feb; 87(4):304-9. PubMed ID: 7707422
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
6. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
7. Recombinant platelet factor 4 for heparin neutralization.
Mixon TA; Dehmer GJ
Semin Thromb Hemost; 2004 Jun; 30(3):369-77. PubMed ID: 15282660
[TBL] [Abstract][Full Text] [Related]
8. Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera?
Lippi G; Favaloro EJ
Semin Thromb Hemost; 2010 Jul; 36(5):558-69. PubMed ID: 20632253
[TBL] [Abstract][Full Text] [Related]
9. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis.
Yamaguchi K; Ogawa K; Katsube T; Shimao K; Konno S; Shimakawa T; Yoshimatsu K; Naritaka Y; Yagawa H; Hirose K
Anticancer Res; 2005; 25(2A):847-51. PubMed ID: 15868918
[TBL] [Abstract][Full Text] [Related]
10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
11. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of recombinant platelet factor 4 and protamine sulfate for heparin neutralization: clotting and clearance studies in rat.
Korutla LN; Stewart GJ; Lasz EC; Maione TE; Niewiarowski S
Thromb Haemost; 1994 May; 71(5):609-14. PubMed ID: 8091389
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of tumor angiogenesis in nude mice by adenovirus-mediated PF4 p17-70 cDNA transfection].
Wu LH; Song GL; Diao SY; Cai YL; Li YH; Li SZ; Yang RC; Han ZC
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):426-9. PubMed ID: 14642182
[TBL] [Abstract][Full Text] [Related]
14. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of platelet factor 4 (PF4) on the growth of human erythroleukemia cells: proposed mechanism of action of PF4.
Han ZC; Maurer AM; Bellucci S; Wan HY; Kroviarski Y; Bertrand O; Caen JP
J Lab Clin Med; 1992 Oct; 120(4):645-60. PubMed ID: 1402341
[TBL] [Abstract][Full Text] [Related]
16. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis.
Struyf S; Burdick MD; Peeters E; Van den Broeck K; Dillen C; Proost P; Van Damme J; Strieter RM
Cancer Res; 2007 Jun; 67(12):5940-8. PubMed ID: 17575164
[TBL] [Abstract][Full Text] [Related]
17. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
18. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression.
Dirkx AE; Oude Egbrink MG; Kuijpers MJ; van der Niet ST; Heijnen VV; Bouma-ter Steege JC; Wagstaff J; Griffioen AW
Cancer Res; 2003 May; 63(9):2322-9. PubMed ID: 12727857
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.
Maione TE; Gray GS; Petro J; Hunt AJ; Donner AL; Bauer SI; Carson HF; Sharpe RJ
Science; 1990 Jan; 247(4938):77-9. PubMed ID: 1688470
[TBL] [Abstract][Full Text] [Related]
20. [Bioassay of recombinant human platelet factor 4].
Han Z; Shen Q; Han Z
Zhonghua Xue Ye Xue Za Zhi; 1997 Mar; 18(3):123-5. PubMed ID: 15622770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
